Clinical Trials
168 trialsNatural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
National Institutes of Health Clinical Center (CC)
CAN3001
Janssen Research & Development, LLC
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
National Institutes of Health Clinical Center (CC)
TAILOR
Janssen Research & Development, LLC
QOLIBRI
Janssen Cilag S.A.S.
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
REALITY-RO
Janssen Research & Development, LLC
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Institutes of Health Clinical Center (CC)
CaDAnCe-101
BeOne Medicines
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Dizal Pharmaceuticals
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Ohio State University Comprehensive Cancer Center
CaDAnCe-302
BeOne Medicines
BELLWAVE-011
Merck Sharp & Dohme LLC
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
AQUALIS
AstraZeneca
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
BOSon
Massachusetts General Hospital
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
BELLWAVE-010
Merck Sharp & Dohme LLC
Soundtrack-E
AstraZeneca
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
SIGMA
Grifols Biologicals, LLC
CaDAnCe-303
BeOne Medicines
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Canadian Cancer Trials Group
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Institutes of Health Clinical Center (CC)
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
TITANium
AstraZeneca
CLL2000
German CLL Study Group
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Dana-Farber Cancer Institute
Understanding Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center